[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SE0202134D0 - Therapeutic agents - Google Patents

Therapeutic agents

Info

Publication number
SE0202134D0
SE0202134D0 SE0202134A SE0202134A SE0202134D0 SE 0202134 D0 SE0202134 D0 SE 0202134D0 SE 0202134 A SE0202134 A SE 0202134A SE 0202134 A SE0202134 A SE 0202134A SE 0202134 D0 SE0202134 D0 SE 0202134D0
Authority
SE
Sweden
Prior art keywords
sup
sub
group
optionally substituted
fluoro
Prior art date
Application number
SE0202134A
Other languages
English (en)
Inventor
Kay Brickmann
Anna Linusson
Asim Ray
Pernilla Sandberg
Anette Svensson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0202134A priority Critical patent/SE0202134D0/sv
Publication of SE0202134D0 publication Critical patent/SE0202134D0/sv
Priority to TW092118207A priority patent/TW200412957A/zh
Priority to PL03374674A priority patent/PL374674A1/xx
Priority to BR0312312-0A priority patent/BR0312312A/pt
Priority to CA002491835A priority patent/CA2491835A1/en
Priority to US10/520,372 priority patent/US20060247439A1/en
Priority to CN038160749A priority patent/CN1665502A/zh
Priority to RU2004138079/04A priority patent/RU2004138079A/ru
Priority to AU2003281194A priority patent/AU2003281194A1/en
Priority to PCT/GB2003/002884 priority patent/WO2004004726A1/en
Priority to EP03740771A priority patent/EP1528924A1/en
Priority to JP2004518963A priority patent/JP2006501186A/ja
Priority to MXPA05000336A priority patent/MXPA05000336A/es
Priority to AR20030102464A priority patent/AR040476A1/es
Priority to IL16584104A priority patent/IL165841A0/xx
Priority to NO20045528A priority patent/NO20045528L/no
Priority to ZA200500030A priority patent/ZA200500030B/en
Priority to IS7653A priority patent/IS7653A/is
Priority to CO05007427A priority patent/CO5680403A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Quinoline Compounds (AREA)
SE0202134A 2002-07-08 2002-07-08 Therapeutic agents SE0202134D0 (sv)

Priority Applications (19)

Application Number Priority Date Filing Date Title
SE0202134A SE0202134D0 (sv) 2002-07-08 2002-07-08 Therapeutic agents
TW092118207A TW200412957A (en) 2002-07-08 2003-07-03 Therapeutic agents
MXPA05000336A MXPA05000336A (es) 2002-07-08 2003-07-04 Antagonistas del receptor 1 de hormona de concentracion de melanina (mchir).
AU2003281194A AU2003281194A1 (en) 2002-07-08 2003-07-04 Mchir antagonists
JP2004518963A JP2006501186A (ja) 2002-07-08 2003-07-04 Ｍｃｈ１ｒアンタゴニスト
CA002491835A CA2491835A1 (en) 2002-07-08 2003-07-04 Mch1r antagonists
US10/520,372 US20060247439A1 (en) 2002-07-08 2003-07-04 Mchir antagonists
CN038160749A CN1665502A (zh) 2002-07-08 2003-07-04 Mchir拮抗剂
RU2004138079/04A RU2004138079A (ru) 2002-07-08 2003-07-04 Антагонисты рецептора-1 меланин-концентрирующего гормона (мсн1r)
PL03374674A PL374674A1 (en) 2002-07-08 2003-07-04 Mchir antagonists
PCT/GB2003/002884 WO2004004726A1 (en) 2002-07-08 2003-07-04 Mchir antagonists
EP03740771A EP1528924A1 (en) 2002-07-08 2003-07-04 Mch1r antagonists
BR0312312-0A BR0312312A (pt) 2002-07-08 2003-07-04 Composto, formulação farmacêutica, uso de um composto, processo para a preparação de compostos, e, intermediários
AR20030102464A AR040476A1 (es) 2002-07-08 2003-07-08 N-cicloalquil, aril o heteroaril n'-quinolin-2-il alquildiaminas y su uso como antagonistas de mch (hormona concentradora de melanina)
IL16584104A IL165841A0 (en) 2002-07-08 2004-12-16 Mchir antagonists
NO20045528A NO20045528L (no) 2002-07-08 2004-12-17 MHC1R-antagonister
ZA200500030A ZA200500030B (en) 2002-07-08 2005-01-03 MCH1r antagonists.
IS7653A IS7653A (is) 2002-07-08 2005-01-19 MCHIR mótlyf
CO05007427A CO5680403A2 (es) 2002-07-08 2005-01-28 Antagonistas de mchr1r

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0202134A SE0202134D0 (sv) 2002-07-08 2002-07-08 Therapeutic agents

Publications (1)

Publication Number Publication Date
SE0202134D0 true SE0202134D0 (sv) 2002-07-08

Family

ID=20288471

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0202134A SE0202134D0 (sv) 2002-07-08 2002-07-08 Therapeutic agents

Country Status (19)

Country Link
US (1) US20060247439A1 (sv)
EP (1) EP1528924A1 (sv)
JP (1) JP2006501186A (sv)
CN (1) CN1665502A (sv)
AR (1) AR040476A1 (sv)
AU (1) AU2003281194A1 (sv)
BR (1) BR0312312A (sv)
CA (1) CA2491835A1 (sv)
CO (1) CO5680403A2 (sv)
IL (1) IL165841A0 (sv)
IS (1) IS7653A (sv)
MX (1) MXPA05000336A (sv)
NO (1) NO20045528L (sv)
PL (1) PL374674A1 (sv)
RU (1) RU2004138079A (sv)
SE (1) SE0202134D0 (sv)
TW (1) TW200412957A (sv)
WO (1) WO2004004726A1 (sv)
ZA (1) ZA200500030B (sv)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200507112B (en) * 2003-03-31 2007-03-28 Taisho Pharmaceutical Co Ltd Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof
EP1464335A3 (en) * 2003-03-31 2007-05-09 Taisho Pharmaceutical Co. Ltd. Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist
US20070185079A1 (en) * 2004-01-07 2007-08-09 Astrazeneca Ab Therapeutic agents I
GB0400193D0 (en) * 2004-01-07 2004-02-11 Astrazeneca Ab Therapeutic agents
EP1730122A2 (en) * 2004-03-30 2006-12-13 Taisho Pharmaceutical Co., Ltd Pyrimidine derivatives and methods of treatment related to the use thereof
WO2006015279A1 (en) * 2004-07-28 2006-02-09 Neurogen Corporation Heterocyclic diamine compounds as ligands of the melanin concentrating hormone receptor useful for the treatment of obesity, diabetes, eating and sexual disorders
WO2006035967A1 (en) * 2004-09-30 2006-04-06 Taisho Pharmaceutical Co., Ltd. Pyridine derivatives and their use as medicaments for treating diseases related to mch receptor
AU2005316314B2 (en) * 2004-12-17 2011-06-23 Eli Lilly And Company Thiazolopyridinone derivates as MCH receptor antagonists
AU2007208405B2 (en) * 2006-01-25 2011-05-26 Merck Sharp & Dohme Corp. Aminocyclohexanes as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
FR2902100A1 (fr) * 2006-06-13 2007-12-14 Sanofi Aventis Sa Molecules duales contenant un derive peroxydique, leur synthese et leurs applications en therapeutique
CA2664031A1 (en) 2006-09-28 2008-04-03 F. Hoffmann-La Roche Ag Quinoline derivatives with 5-ht-binding properties
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
CN102271509A (zh) 2008-10-31 2011-12-07 默沙东公司 用于抗糖尿病药的新型环苯并咪唑衍生物
SA110310332B1 (ar) 2009-05-01 2013-12-10 Astrazeneca Ab مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل )
KR102505085B1 (ko) 2009-12-04 2023-02-28 선오비온 파마슈티컬스 인코포레이티드 다환형 화합물 및 이의 사용 방법
CA2786314A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
ES2527466T3 (es) 2010-07-06 2015-01-26 Astrazeneca Ab Agentes terapéuticos 976
CN103476258B (zh) 2011-02-25 2017-04-26 默沙东公司 用作抗糖尿病药剂的新的环状氮杂苯并咪唑衍生物
UY34194A (es) 2011-07-15 2013-02-28 Astrazeneca Ab ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
CA2880901A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
RU2015140066A (ru) 2013-02-22 2017-03-30 Мерк Шарп И Доум Корп. Противодиабетические бициклические соединения
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
AU2017301769B2 (en) 2016-07-29 2022-07-28 Pgi Drug Discovery Llc Compounds and compositions and uses thereof
JP2019523279A (ja) 2016-07-29 2019-08-22 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 化合物および組成物ならびにそれらの使用
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
US10968232B2 (en) 2016-12-20 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
PL3557998T3 (pl) * 2016-12-23 2024-03-11 Aquinnah Pharmaceuticals Inc. Związki, kompozycje i sposoby ich stosowania
MX2019009763A (es) 2017-02-16 2019-11-21 Sunovion Pharmaceuticals Inc Metodos para tratar esquizofrenia.
JP7191085B2 (ja) 2017-08-02 2022-12-16 サノビオン ファーマシューティカルズ インク イソクロマン化合物およびその使用
US10815249B2 (en) 2018-02-16 2020-10-27 Sunovion Pharmaceuticals Inc. Salts, crystal forms, and production methods thereof
JP2022525169A (ja) 2019-03-14 2022-05-11 サノビオン ファーマシューティカルズ インク イソクロマニル化合物の塩およびその結晶体、ならびにそれらの製造方法、治療用途および医薬組成物
MX2022012833A (es) 2020-04-14 2022-11-07 Sunovion Pharmaceuticals Inc (s)-(4,5-dihidro-7h-tieno[2,3-c]piran-7-il)-n-metilmetanamina para tratar trastornos neurologicos y psiquiatricos.
US20240217951A1 (en) 2022-09-23 2024-07-04 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
US20240228469A1 (en) 2022-09-23 2024-07-11 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
US20240239767A1 (en) 2022-12-16 2024-07-18 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3020283A (en) * 1958-10-20 1962-02-06 Abbott Lab Bis-lepidines
AU7997091A (en) * 1990-05-30 1991-12-31 American Home Products Corporation Substituted arylsulfonamides and benzamides
AU2764797A (en) * 1996-05-14 1997-12-05 Novo Nordisk A/S Somatostatin agonists and antagonists
EP0973513A4 (en) * 1996-10-23 2003-03-19 Zymogenetics Inc COMPOSITIONS AND METHODS FOR TREATING CONDITIONS ASSOCIATED WITH BONE DEFICIT
WO1999055677A1 (en) * 1998-04-29 1999-11-04 Smithkline Beecham Plc Quinolones used as mrs inhibitors and bactericides
US6489344B1 (en) * 1998-06-19 2002-12-03 Chiron Corporation Inhibitors of glycogen synthase kinase 3
PT1285651E (pt) * 2000-04-28 2010-10-21 Takeda Pharmaceutical Antagonistas da hormona concentradora da melanina
US20040180925A1 (en) * 2000-12-27 2004-09-16 Kenji Matsuno Dipeptidylpeptidase-IV inhibitor
WO2002058702A1 (en) * 2001-01-26 2002-08-01 Smithkline Beecham Corporation Urotensin-ii receptor antagonists

Also Published As

Publication number Publication date
NO20045528L (no) 2005-04-04
TW200412957A (en) 2004-08-01
CN1665502A (zh) 2005-09-07
WO2004004726A1 (en) 2004-01-15
RU2004138079A (ru) 2005-08-10
CA2491835A1 (en) 2004-01-15
AR040476A1 (es) 2005-04-06
ZA200500030B (en) 2005-11-11
MXPA05000336A (es) 2005-03-31
AU2003281194A1 (en) 2004-01-23
US20060247439A1 (en) 2006-11-02
EP1528924A1 (en) 2005-05-11
IS7653A (is) 2005-01-19
CO5680403A2 (es) 2006-09-29
BR0312312A (pt) 2005-04-12
IL165841A0 (en) 2006-01-15
PL374674A1 (en) 2005-10-31
JP2006501186A (ja) 2006-01-12

Similar Documents

Publication Publication Date Title
SE0202134D0 (sv) Therapeutic agents
AR046186A1 (es) Compuestos derivados de 1,3,8-triaza-espiro[4.5]decan-4-ona
HUP0303148A2 (hu) CB1 antagonista hatású 4,5-dihidro-1H-pirazol-származékok és e vegyületeket tartalmazó gyógyászati készítmények és eljárások az előállításukra
MX2007006896A (es) Fenil-metanonas bi- y triciclicas sustituidas como inhibidores del transportador 1 de glicina (glyt-1) para el tratamiento de la enfermedad de alzheimer.
RU2008111991A (ru) Органические соединения
SE0104332D0 (sv) Therapeutic agents
HRP20050708A2 (en) Piperidine-benzenesulfonamide derivatives
HUP0402107A2 (hu) N-helyettesített pirrolidinszármazékok, mint dipeptidil-peptidáz IV inhibítorok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
IS6459A (is) Arýl sambrædd azapólýsýklísk efnasambönd
HUP0301671A2 (hu) 4-Fenil-piridin-származékok, mint neurokinin-1-receptor antagonisták, eljárás az előállításukra és alkalmazásuk
NO20015686L (no) Nye forbindelser, deres anvendelse og fremstilling
EA200870358A1 (ru) 2-(циклический амино) пиримидоновые производные в качестве ингибиторов tpk1
EA200601192A1 (ru) ЗАМЕЩЁННЫЕ ПРОИЗВОДНЫЕ 8'-ПИРИ(МИ)ДИНИЛДИГИДРОСПИРО[ЦИКЛОАЛКИЛАМИН]ПИРИМИДО[1,2-a]ПИРИМИДИН-6-ОНА
RU2009103307A (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[1, 2-a]ПИРИДИН-2-КАРБОКСАМИДОВ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В ТЕРАПИИ
HUP0203874A2 (hu) Helyettesített 4-(fenil-N-alkil)piperazin és piperidinszármazékok és alkalmazásuk dopamin neurotranszmissziós modulátorként és ezeket tartalmazó gyógyszerkészítmények
MXPA05002420A (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos.
MXPA05010112A (es) Derivados 8-perfluoroalquil-6, 7, 8, 9-tetrahidropirimido [1,2-a] pirimidin-4 -ona substituidos.
MX2009009384A (es) Malonamidas como antagonistas de orexina.
MX2009009121A (es) Aminoamidas como antagonistas de orexina.
MXPA05009574A (es) Derivados de 8'-piridinil- dihidrospiro -[cicloalquil]- pirimido[1, 2a] pirimidin-6- ona y y 8'-pirimidinil- dihidrospiro -[cicloalquil]- pirimido [1, 2a]pirimidin-6 -ona substituidos y su uso contra enfermedades neurodegenerativas.
WO2004082577A3 (en) 8-SUBSTITUTED-6, 7, 8, 9-TETRAHYDROPYRIMIDO[1,2-a] PYRIMIDIN-4-ONE DERIVATIVES
TW200621760A (en) 2-morpholino-4-pyrimidone compound
MX2007003722A (es) Derivados de 6-(piridinil)-4-pirimidona como inhibidores de la tau proteina cinasa 1.
MX2011007272A (es) Piperidinas de aroilamino y heteroaroilamino sustituidas como inhibidores de glyt-1.
HUP0401883A2 (hu) Muszkarin agonisták és ezeket tartalmazó gyógyászati készítmények